Abstract
Renal replacement therapy (RRT) remains associated with a significant risk of serious complications, and critically ill patients requiring RRT continue to manifest particularly poor overall survival rates. These poor outcomes persist despite improvements in the modalities employed as well as an enhanced understanding of the effects of the extracorporeal circuit, anticoagulation, treatment doses, fluid replacement and dialysis membrane. More recently, there has been an emerging appreciation that intermittent RRT (in the chronic maintenance haemodialysis setting) is capable of generating sufficient circulatory stress to propagate additional widespread end-organ injury. The mitigation of this plethora of risks by the correct identification of complications, targeting of therapy refinements and prediction, whilst problems still remain occult, is desirable and becoming increasingly possible in the pursuit of improved outcomes in this high-mortality therapeutic field.
References
1.
Fonseca Ruiz NJ, Castro DP, Guerra AM, Saldarriaga FM, Hernandez JD: Renal injury study in critical ill patients in accordance with the new definition given by the acute kidney injury network. J Crit Care 2011;26:206–212.
2.
Verma AK, Levine M, Shalansky SJ, Carter CJ, Kelton JG: Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 2003;23:745–753.
3.
Joannidis M, Kountchev J, Rauchenzauner M, Schusterschitz N, Ulmer H, Mayr A, Bellmann R: Enoxaparin vs unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Med 2007;33:1571–1579.
4.
Panphanpho S, Naowapanich S, Ratanarat R: Use of saline flush to prevent filter clotting in continuous renal replacement therapy without anticoagulant. J Med Assoc Thai 2011;94(suppl 1):S105–S110.
5.
Wu MY, Hsu YH, Bai CH, Lin YF, Wu CH, Tam KW: Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2012;59:810–818.
6.
Kutsogiannis DJ, Gibney RT, Stollery D, Gao J: Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005;67:2361–2367.
7.
Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P: Citrate vs heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004;30:260–265.
8.
Gritters M, Grooteman MP, Schoorl M, Bartels PC, Scheffer PG, Teerlink T, Schalkwijk CG, Spreeuwenberg M, Nube MJ: Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant 2006;21:153–159.
9.
Tiranathanagul K, Jearnsujitwimol O, Susantitaphong P, Kijkriengkraikul N, Leelahavanichkul A, Srisawat N, Praditpornsilpa K, Eiam-Ong S: Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Ther Apher Dial 2012;15:556–564.
10.
Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF: Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009;37:545–552.
11.
Hetzel GR, Schmitz M, Wissing H, Ries W, Schott G, Heering PJ, Isgro F, Kribben A, Himmele R, Grabensee B, Rump LC: Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 2011;26:232–239.
12.
Davenport A, Tolwani A: Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit. NDT Plus 2009;2:439–447.
13.
Shum HP, Chan KC, Yan WW: Regional citrate anticoagulation in predilution continuous venovenous hemofiltration using prismocitrate 10/2 solution. Ther Apher Dial 2012;16:81–86.
14.
Sands JJ, Kotanko P, Segal JH, Ho CH, Usvat L, Young A, Carter M, Sergeyeva O, Korth L, Maunsell E, Zhu Y, Krishnan M, Diaz-Buxo JA: Effects of citrate acid concentrate (citrasate®) on heparin N requirements and hemodialysis adequacy: a multicenter, prospective noninferiority trial. Blood Purif 2012;33:199–204.
15.
Tu A, Ahmad A: Heparin-free hemodialysis with citrate-containing dialysate in intensive care patients. Dial Transplant 2000;29:620–626.
16.
Clark JA, Schulman G, Golper TA: Safety and efficacy of regional citrate anticoagulation during 8-hour sustained low-efficiency dialysis. Clin J Am Soc Nephrol 2008;3:736–742.
17.
Rabindranath KS, Kumar E, Shail R, Vaux E: Use of real-time ultrasound guidance for the placement of hemodialysis catheters: a systematic review and meta-analysis of randomized controlled trials. Am J Kidney Dis 2011;58:964–970.
18.
O’Grady NP, Alexander A, Burns LA, Patchen-Dellinger E, Garland J, Heard SO, Lipsett PA, Masur H, Mermel LA, Pearson ML, Raad II, Randolph A, Rupp ME, Saint S: Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011;52:e162–e193.
19.
Merrer J, De Jonghe B, Golliot F, Lefrant JY, Raffy B, Barre E, Rigaud JP, Casciani D, Misset B, Bosquet C, Outin H, Brun-Buisson C, Nitenberg G: Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA 2001;286:700–707.
20.
Veenstra DL, Saint S, Saha S, Lumley T, Sullivan SD: Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA 1999;281:261–267.
21.
Jaffer Y, Selby NM, Taal MW, Fluck RJ, McIntyre CW: A meta-analysis of hemodialysis catheter locking solutions in the prevention of catheter-related infection. Am J Kidney Dis 2008;51:233–241.
22.
Bleyer AJ, Hartman J, Brannon PC, Reeves-Daniel A, Satko SG, Russell G: Characteristics of sudden death in hemodialysis patients. Kidney Int 2006;69:2268–2273.
23.
Pun PH, Lehrich RW, Honeycutt EF, Herzog CA, Middleton JP: Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. Kidney Int 2010;79:218–227.
24.
Karnik JA, Young BS, Lew NL, Herget M, Dubinsky C, Lazarus JM, Chertow GM: Cardiac arrest and sudden death in dialysis units. Kidney Int 2001;60:350–357.
25.
Daugirdas JT, Blake PG, Ing TS: Handbook of Dialysis, ed 4. Philadelphia, Lippincott Williams & Wilkins, 2007.
26.
Chan KE, Lazarus JM, Hakim RM: Digoxin associates with mortality in esrd. J Am Soc Nephrol 2010;21:1550–1559.
27.
Zazzo JF, Troche G, Ruel P, Maintenant J: High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus therapy on myocardial function. Intensive Care Med 1995;21:826–831.
28.
Broman M, Carlsson O, Friberg H, Wieslander A, Godaly G: Phosphate-containing dialysis solution prevents hypophosphatemia during continuous renal replacement therapy. Acta Anaesthesiol Scand 2011;55:39–45.
29.
Kumar VA, Yeun JY, Depner TA, Don BR: Extended daily dialysis vs continuous hemodialysis for ICU patients with acute renal failure: a two-year single center report. Int J Artif Organs 2004;27:371–379.
30.
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368–1377.
31.
Bouchard J, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, Mehta RL: Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int 2009;76:422–427.
32.
Bagshaw SM, Baldwin I, Fealy N, Bellomo R: Fluid balance error in continuous renal replacement therapy: a technical note. Int J Artif Organs 2007;30:434–440.
33.
McIntyre CW: Effects of hemodialysis on cardiac function. Kidney Int 2009;76:371–375.
34.
McIntyre CW: Haemodialysis-induced myocardial stunning in chronic kidney disease – a new aspect of cardiovascular disease. Blood Purif 2010;29:105–110.
35.
Selby NM, McIntyre CW: The acute cardiac effects of dialysis. Semin Dial 2007;20:220–228.
36.
John S, Griesbach D, Baumgartel M, Weihprecht H, Schmieder RE, Geiger H: Effects of continuous haemofiltration vs intermittent haemodialysis on systemic haemodynamics and splanchnic regional perfusion in septic shock patients: a prospective, randomized clinical trial. Nephrol Dial Transplant 2001;16:320–327.
37.
Jefferies HJ, Virk B, Schiller B, Moran J, McIntyre CW: Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). Clin J Am Soc Nephrol 2011;6:1326–1332.
38.
Kielstein JT, Kretschmer U, Ernst T, Hafer C, Bahr MJ, Haller H, Fliser D: Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. Am J Kidney Dis 2004;43:342–349.
39.
Selby NM, Burton JO, Chesterton LJ, McIntyre CW: Dialysis-induced regional left ventricular dysfunction is ameliorated by cooling the dialysate. Clin J Am Soc Nephrol 2006;1:1216–1225.
40.
Zhou F, Song Q, Peng Z, Pan L, Kang H, Tang S, Yue H, Liu H, Xie F: Effects of continuous venous-venous hemofiltration on heat stroke patients: a retrospective study. J Trauma 2011;71:1562–1568.
41.
Aslami H, Juffermans NP: Induction of a hypometabolic state during critical illness – a new concept in the ICU? Neth J Med 2010;68:190–198.
42.
Eldehni MT, McIntyre CW: Are there neurological consequences of recurrent intradialytic hypotension? Semin Dial 2012;25:253–256.
43.
McIntyre CW, Harrison LE, Eldehni MT, Jefferies HJ, Szeto CC, John SG, Sigrist MK, Burton JO, Hothi D, Korsheed S, Owen PJ, Lai KB, Li PK: Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 2010;6:133–141.
44.
Conger JD: Does hemodialysis delay recovery from acute renal failure? Semin Dial 1990;3:146–148.
45.
Chesterton LJ, Selby NM, Burton JO, Fialova J, Chan C, McIntyre CW: Categorization of the hemodynamic response to hemodialysis: the importance of baroreflex sensitivity. Hemodial Int 2009;14:18–28.
46.
Owen PJ, Priestman WS, Sigrist MK, Lambie SH, John SG, Chesterton LJ, McIntyre CW: Myocardial contractile function and intradialytic hypotension. Hemodial Int 2009;13:293–300.
47.
Cavalcanti S, Severi S, Chiari L, Avanzolini G, Enzmann G, Bianco G, Panzetta G: Autonomic nervous function during haemodialysis assessed by spectral analysis of heart-rate variability. Clin Sci (Lond) 1997;92:351–359.
48.
Chesterton LJ, Selby NM, Bennett T, McIntyre CW: Baroreflex sensitivity (brs) is important in blood pressure control during haemodialysis and enhanced by dual chambed paired haemofiltration. Nephrol Dial Transplant 2005;20:v331–v332.
49.
Chan CT, Jain V, Picton P, Pierratos A, Floras JS: Nocturnal hemodialysis increases arterial baroreflex sensitivity and compliance and normalizes blood pressure of hypertensive patients with end-stage renal disease. Kidney Int 2005;68:338–344.
50.
Laude D, Elghozi JL, Girard A, Bellard E, Bouhaddi M, Castiglioni P, Cerutti C, Cividjian A, Di Rienzo M, Fortrat JO, Janssen B, Karemaker JM, Leftheriotis G, Parati G, Persson PB, Porta A, Quintin L, Regnard J, Rudiger H, Stauss HM: Comparison of various techniques used to estimate spontaneous baroreflex sensitivity (the EuroBaVar study). Am J Physiol Regul Integr Comp Physiol 2004;286:R226–R231.
51.
Pignocchino P, Conte MR, Scarnato S, Grande A: Study of cutaneous microcirculation using the laser-Doppler method in syndrome X. Cardiologia 1994;39:193–197.
52.
Economides PA, Caselli A, Zuo CS, Sparks C, Khaodhiar L, Katsilambros N, Horton ES, Veves A: Kidney oxygenation during water diuresis and endothelial function in patients with type 2 diabetes and subjects at risk to develop diabetes. Metabolism 2004;53:222–227.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
